慢性肾脏病不同分期中血浆钾与死亡率相关的范围:SCREAM项目
调整后血浆钾中位数随CKD分期恶化而升高,钾与死亡率呈U形关联,但低eGFR层关联变平且上移;90天死亡率风险增加不超过100%的钾范围在eGFR>60为3.45-4.94 mmol/L,G3为3.36-5.18,G4-G5为3.26-5.53 mmol/L。结论支持晚期CKD对高钾血症耐受更好,但挑战对所有患者使用单一最佳钾范围。
要点
- 调整后血浆钾中位数随eGFR下降而升高,eGFR≤15为4.43 mmol/L。
- 钾与死亡率呈U形关联,但低eGFR层关联变平且上移。
- 90天死亡率风险增加≤100%的钾范围随CKD分期恶化而增宽上移。
核心结论
- CKD分期改变血浆钾分布及预测死亡率的钾范围。
- 研究支持晚期CKD对高钾血症耐受更好,但挑战对所有患者使用单一最佳钾范围。
研究设计与样本
- 随机选取每名患者一次钾测量,构建横断面队列并随访死亡率。
- 共纳入831 760名参与者,其中CKD G3 70 403例(8.5%),CKD G4-G5 8 594例(1.1%)。
- 协变量包括人口学、合并症、药物和eGFR。
- 估计钾分布并定义与90、180、365天死亡率相关的钾范围。
主要发现
- 一年内发生约66 317例死亡。
- 调整后血浆钾中位数从eGFR>90的3.98(95%CI 3.49-4.59)升至eGFR≤15的4.43(3.22-5.65)mmol/L。
- 钾与死亡率关联呈U形,但在较低eGFR层变平且上移。
- 90天死亡率风险增加不超过100%的钾范围:eGFR>60为3.45-4.94 mmol/L,G3为3.36-5.18,G4-G5为3.26-5.53 mmol/L。
关键数值与推荐
- CKD G3定义为eGFR<60-30 mL/min,CKD G4-G5定义为eGFR<30 mL/min。
- 90天死亡率风险增加不超过100%的钾范围:eGFR>60为3.45-4.94 mmol/L,G3为3.36-5.18,G4-G5为3.26-5.53 mmol/L。
临床怎么用
- 临床解读血浆钾时应考虑CKD分期,不宜对所有患者使用单一最佳钾范围。
- 晚期CKD患者可耐受更高钾水平,但需结合分期评估死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Small-scale studies suggest that hyperkalaemia is a less threatening condition in chronic kidney disease (CKD), arguing adaptation/tolerance to potassium (K+) retention. This study formally evaluates this hypothesis by estimating the distribution of plasma K+ and its association with mortality across CKD stages. METHODS: This observational study included all patients undergoing plasma K+ testing in Stockholm during 2006-11. We randomly selected one K+ measurement per patient and constructed a cross-sectional cohort with mortality follow-up. Covariates included demographics, comorbidities, medications and estimated glomerular filtration rate (eGFR). We estimated K+ distribution and defined K+ ranges associated with 90-, 180- and 365-day mortality. RESULTS: Included were 831 760 participants, of which 70 403 (8.5%) had CKD G3 (eGFR <60-30 mL/min) and 8594 (1.1%) had CKD G4-G5 (eGFR <30 mL/min). About 66 317 deaths occurred within a year. Adjusted plasma K+ increased across worse CKD stages: from median 3.98 (95% confidence interval 3.49-4.59) for eGFR >90 to 4.43 (3.22-5.65) mmol/L for eGFR ≤15 mL/min/1.73 m2. The association between K+ and mortality was U-shaped, but it flattened at lower eGFR strata and shifted upwards. For instance, the range where the 90-day mortality risk increased by no more than 100% was 3.45-4.94 mmol/L in eGFR >60 mL/min, but was 3.36-5.18 in G3 and 3.26-5.53 mmol/L in G4-G5. In conclusion, CKD stage modifies K+ distribution and the ranges that predict mortality in the community. CONCLUSION: Although this study supports the view that hyperkalaemia is better tolerated with worse CKD, it challenges the current use of a single optimal K+ range for all patients.
引用
- Gasparini A, Evans M, Barany P, et al. Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project. Nephrol Dial Transplant. 2019. PMID: 30085251. doi:10.1093/ndt/gfy249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。